Intelligence · Patents
Patents expiring in 2034
Annual patent cliff calendar for 2034 — US pharmaceutical patents by expiration date.
- Patents
- 1,452
Quick answer
1,452 indexed pharmaceutical patents have expiration dates in 2034. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8859774
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 8859727
Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
granted -
US 8859736
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
granted -
US 8859619
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
granted -
US 8859527
Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof
granted -
US 8859520
Methods for therapy of neurodegenerative disease of the brain
granted -
US 8859498
Targeted therapeutic proteins
granted -
US 8858938
Human monoclonal antibodies against Hendra and Nipah viruses
granted -
US 8858946
Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies
granted -
US 8859750
RNAi modulation of RSV and therapeutic uses thereof
granted -
US 8858925
Pegylated fibrinogen precursor molecule
granted -
US 8858930
Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic Escherichia coli in cattle
granted -
US 8858945
Three-dimensional structure of complement receptor type 2 and uses thereof
granted -
US 8859516
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
granted -
US 8858978
Heat cured gel and method of making
granted -
US 8858950
Delivery of pharmaceutical agents via the human insulin receptor
granted -
US 8858959
Gel vaccine delivery system for treating poultry
granted -
US 8859207
Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
granted -
US 8865755
Dual-acting antihypertensive agents
granted -
US 8865873
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
granted -
US 8865914
Fluorescent probes for detection of copper
granted -
US 8865918
Androgen receptor modulator compounds and methods
granted -
US 8865883
Multiple exon skipping compositions for DMD
granted -
US 8865741
Aminoindane compounds and use thereof in treating pain
granted -
US 8865751
Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
granted -
US 8865745
Pyrazolone derivatives as PDE4 inhibitors
granted -
US 8865686
Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors
granted -
US 8865187
Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
granted -
US 8865717
Heterocyclic compounds
granted -
US 8865461
Rabies virus vector systems and compositions and methods thereof
granted -
US 8865750
Small molecule inhibitors of RGS proteins
granted -
US 8865149
Polymeric reagents comprising a ketone or a related functional group
granted -
US 8865771
Amides useful as inhibitors of voltage-gated sodium channels
granted -
US 8865175
Increasing anti-IL-1α antibodies in a subject
granted -
US 8865199
Biomatrix composition and methods of biomatrix seeding
granted -
US 8865430
Fusion polypeptides capable of activating receptors
granted -
US 8865217
Oral preparation comprising pioglitazone
granted -
US 8865230
Compositions and methods for treating parasitic infections
granted -
US 8865210
Stable dosage formulations of imidazolylalkyl-pyridines
granted -
US 8865672
Prevention of tissue ischemia and related methods
granted -
US 8865469
Methods of transforming a Listeria
granted -
US 8865719
Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors
granted -
US 8865694
Topical compositions for treatment of skin conditions
granted -
US 8865722
Wet formulations of aripiprazole
granted -
US 8865728
Combinations comprising methotrexate and DHODH inhibitors
granted -
US 8865723
Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
granted -
US 8865748
Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
granted -
US 8865867
Lectins and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2034?
1,452 published patents in our USPTO index have expiration dates falling in calendar year 2034.